AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06148636
Drug: [212Pb] VMT-α-NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 2 infusions with \[212Pb\] VMT-α-NET, each infusion separated by at least 8 weeks. During each infusion, the participants also receive an infusion with lysine and arginine (amino acids) to help reduce kidney damage.
Trial: NCT05445557
Drug: RZL-012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small synthetic molecule for submental fat reduction
Trial: NCT05445557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06630364
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: Sevoflurane in N2O/O2 Analgesia: Propofol (1-1.5 mg/kg), Fentanyl (1 µg/kg) Maintenance: Sevoflurane
Trial: NCT05423496
Drug: steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimization of steroids
Trial: NCT06490536
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is used as part of the chemotherapy regimens for patients with ctDNA+ and ctDNA- results in the SAGITTARIUS trial. It is administered in the following ways:~CAPOX Regimen: Capecitabine 1000 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle, in combination with oxaliplatin 130 mg/m² given intravenously on day 1.~Capecitabine Monotherapy for High-Risk ctDNA- Patients: Capecitabine 1250 mg/m² is taken orally twice daily on days 1-14 of each 21-day cycle for patients identified as high-risk but with negative ctDNA results.~The dosage of capecitabine is standardized, while the duration of treatment varies based on patient response and monitoring results, typically up to 6 months.
Trial: NCT06490536
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil is used as part of the FOLFOX chemotherapy regimen for patients with ctDNA+ results in the SAGITTARIUS trial. It is administered in the following way:~FOLFOX Regimen: Fluorouracil 400 mg/m² is given as an intravenous (IV) bolus on day 1, followed by 2400 mg/m² as a continuous IV infusion over 46 hours, in combination with folinic acid (leucovorin) 400 mg/m² IV on day 1 and oxaliplatin 85 mg/m² IV on day 1. This regimen is repeated every 14 days.~The dosage of fluorouracil is standardized, while the duration of treatment is typically up to 6 months, adjusted based on patient response and liquid biopsy results.
Trial: NCT04778813
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each study site, children fulfilling the inclusion criteria will be assigned randomly to one of three treatment groups: AL, DHA-PPQ or As-Pyr group. Sealed envelopes each containing no more than 10 other small envelopes with randomization numbers and treatment will also be provided. These will be used over time, respecting the ascending order of the numbers to randomly distribute the eligible children after selection in each of the three treatment groups. The treatment to be administered will not be known until after the randomization process. The drugs will be administered based on weight according to the instructions from the drug manufacturer. AL will be administered with fatty food or milk according to the manufacturer's recommendations. All doses of the drug will be administered under the direct supervision of a qualified team member designated by the principal investigator.
Trial: NCT06487000
Drug: Placebo EC-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, QD
Trial: NCT06530576
Drug: Thalidomide and methotrexate
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at a dose of 50-100 mg/QN, Methotrexate 10 mg/m2 orally once a week.
Trial: NCT06435481
Drug: 3D printed chewable formulation of hydrocortisone
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of a novel hydrocortisone formulation provided as chewable tablets. Each tablet, manufactured with a volume dosing device (3D printer), contains a precise dosage of hydrocortisone.
Trial: NCT06435481
Drug: Oral suspension of hydrocortisone
RxNorm normalized name: hydrocortisone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a standard hydrocortisone oral suspension. The solution, based on simple syrup, contains 1mg of hydrocortisone per milliliter.
Trial: NCT05461755
Drug: Topical Tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of striae with topical tretinoin alone
Trial: NCT06577701
Drug: non traditional Chinese medicine (non-TCM)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regulated use of Chinese medicine treatment protocols is included as an exposure factor. Exposure was defined as taking the medication continuously for more than 3 months per year, or taking the medication intermittently for more than 6 months per year. According to the standardised use of TCM protocols, the group was divided into an exposed group (TCM protocols cohort) and a non-exposed group (non-TCM protocols cohort).
Trial: NCT04836962
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2cc of normal saline is administered to patient instead of dexamethasone.
Trial: NCT05969457
Drug: Naropeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia with injection of Ropivacaine (20mL of ropivacaine 7.5 mg/mL, i.e. 150mg)
Trial: NCT06461299
Drug: Seysara Oral Product
RxNorm normalized name: Seysara Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with a clinical diagnosis of POD will be given sarecycline for four weeks. Dosing of sarecycline will be weight based, either 60mg, 100mg, or 150mg PO qday. Each subject will have at least three visits, including a screening/baseline visit, a two-week follow-up, and a four-week follow-up. The initial diagnosis will be made by a board-certified dermatologist or a dermatology-certified nurse practitioner. The Perioral Dermatitis Severity Index, PODSI, (Appendix I) will be used to grade the severity of periorificial dermatitis throughout the three visits. This published scoring method ranges from 0 to 9. To be included in the study, patients must need to have a PODSI score of moderate (PODSI = 3.0-5.5) or severe (PODSI = 6.0-9.0) at baseline. The primary endpoint is the percentage of patients that receive a PODSI score ranging from 0 (none) to 2.5 (mild) at week four. The secondary endpoint is the patient reported an adverse event at week four.
Trial: NCT06141330
Drug: Azithromycin 250 milligram Oral Capsule
RxNorm normalized name: azithromycin 250 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Anti Biotic
Trial: NCT05867654
Drug: oral clindamycin 300mg q6hrs
RxNorm normalized name: clindamycin 300 MG
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral antibiotic used based on indication
Trial: NCT05953688
Drug: ESK-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06576388
Drug: EXG001-307 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Research process includes filter (subjects signed informed consent for screening period before the pretreatment to the hormone, the longest 28 days), treatment period (the subjects accept including single hormone pretreatment, the study drug infusion) hospitalization and observation and follow-up treatment period (subjects to the participants to 18 months, lost to follow-up, active exit research subjects, or death). Subjects qualified in the screening period entered the treatment period and received EXG001-307, and entered the follow-up period after hospitalization. At the end of the study visit (subject at 18 months of age), eligible subjects will be asked to transfer to the long-term follow-up study.
Trial: NCT05018923
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1g bid
Trial: NCT05018923
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g qid
Trial: NCT05004909
Drug: 0.05% Tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization
Trial: NCT05650645
Drug: Placebo-Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
Trial: NCT05417880
Drug: Oral Hypoglycemic Agents,Oral
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with routine current oral hypoglycemic agents for 3-6 months
Trial: NCT05417880
Drug: Voreta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
Trial: NCT00035074
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06666673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as control
Trial: NCT05765279
Drug: Placebo Comparator 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray 5 times daily for 3 consecutive days
Trial: NCT05765279
Drug: Placebo Comparator 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray 8 times daily for 3 consecutive days
Trial: NCT06562894
Drug: SYHX1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily (QD)
Trial: NCT06562894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily (QD)
Trial: NCT06659094
Drug: conventional medical treatment (TAU)
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy, managed by a deputy chief psychiatrist unaware of patient groupings, utilizes China Food and Drug Administration (CFDA)-approved SSRIs for OCD. These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine. The maximum dosage adheres to the instructions. Benzodiazepines may assist with sleep, but usage is capped at two weeks; no other psychotropics are co-administered. Common side effects comprise dry mouth, constipation, nausea, indigestion, dizziness, fatigue, and sweating. The maximum dosage shall not exceed the maximum dosage prescribed in the instruction manual.
Trial: NCT05435781
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Trial: NCT05435781
Drug: Placebo for hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Trial: NCT05204862
Drug: TU2218
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered
Trial: NCT05901441
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For those in SF group: they will be administered with 40 ug/ml sufentanil
Trial: NCT06425549
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants receive placebo at pre-specified timepoints during the study to maintain the blinding.
Trial: NCT06133751
Drug: black chokeberry (Aronia melanocarpa)
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black chokeberry capsules standardized for anthocyanin compounds
Trial: NCT06133751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chokeberry fiber placebo capsules
Trial: NCT06106412
Drug: A23187
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oocytes will be activated with A23187
Trial: NCT05299554
Drug: Chronocort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone modified-release capsule 5 mg and 10 mg
Trial: NCT04717531
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, day 1
Trial: NCT06387212
Drug: 35 kDa hyaluronan fragment HA35 injection
RxNorm normalized name: PALMITOYL FRAGMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First, apply an appropriate amount of compound lidocaine cream to the treatment site ( national drug approval number H20063466 ; Beijing Ziguang Pharmaceutical Co., Ltd. ) waited for 60 minutes after applying hemp, and then injected the syringe containing sterile HA35 prepared in advance into the subcutaneous 1.0-1.5mm through the DermaShine PRO negative pressure microneedle importer ( Demasha, South Korea ).
Trial: NCT05865496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous (SC) injection.
Trial: NCT04971135
Drug: SAN711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAN711 liquid formulation
Trial: NCT05840211
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04593511
Drug: LY03009 F1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of LY03009 F1
Trial: NCT04593511
Drug: LY03009 F2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of LY03009 F2
Trial: NCT04593511
Drug: LY03009 F3
RxNorm normalized name: MLK F3 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of LY03009 F3
Trial: NCT04593511
Drug: LY03009 F4
RxNorm normalized name: MLK F4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of LY03009 F4
Trial: NCT04954001
Drug: FCN-159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCN-159 is administered orally in once daily schedule for 28 days a cycle.
Trial: NCT06501391
Drug: PD-L1/PD-1 inhibitor and chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable brain metastases patients in this arm will receive PD-L1/PD-1 inhibitors and chemotherapy.
Trial: NCT05752799
Drug: Opioid Free Anaesthesia
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Trial: NCT05752799
Drug: Opioid based anesthesia
RxNorm normalized name: Opioid anesthetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value \> 25 or elevation of Heart Rate and/or Blood Pressure \>20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Trial: NCT05105542
Drug: 11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.
Trial: NCT06640257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04866160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05835011
Drug: Decitabine/Cedazuridine
RxNorm normalized name: decitabine/cedazuridine 35 mg-100 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral FDC tablets administration
Trial: NCT04807309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day
Trial: NCT05924191
Drug: Placebo Corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 hour before the surgery a placebo tablet, with the same physical and organoleptic characteristics, composed of corn starch, without harmful effects on health and simulating Dexamethasone (Celsius Laboratory, Montevideo, Uruguay).).
Trial: NCT05924191
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)
Trial: NCT05846490
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive treatment intensification (if necessary)
Trial: NCT06371495
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stude include three groupsof people GroupA: recieve rosuvastatin 40mg Group B :recive rosuvastatin 20mg Group C: recive placebo 2- Follow up will be done using NIHSS at the onset and modified Rankin scale at the onset and after 1 month and 3 months of the onset.~3- Carotid duplex will be done at the onset and after 1 month and 3 months of the onset.
Trial: NCT06140758
Drug: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will use this product during one of the six treatment periods in the crossover study design.
Trial: NCT06177535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three capsules orally once daily within one hour of bedtime. Looks exactly like the study drug, but it contains no active ingredient.
Trial: NCT05924425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized in the control group will receive the placebo every evening within 30 minutes of going to bed during one month. The treatment period (Period A or Period B) will be followed by a one-week (range 5-12 days) washout period at home.
Trial: NCT06148038
Drug: CBD Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD Oral 350mg twice daily for 28 days
Trial: NCT06252493
Drug: Radiotracer Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Gallium-68 labeled collagen binding probe 8 (\[68Ga\]CBP8):~All subjects will undergo placement of an intravenous catheter (IV). The catheter will be flushed post-injection of \[68Ga\]CBP8 with 0.9% saline solution.~The subjects will be positioned on the scanner table; support devices under the back and/or legs will be used as needed to enable the patient to comfortably maintain his/her position throughout the scan; Up to 15 mCi of \[68Ga\]CBP8 will be administered. The injected dose and the time of injection will be recorded;~Post scan:~The catheter will be removed. The subject will be asked to void again immediately after the scan and he/she will be counseled on the importance of continuing to drink fluids for several more hours in order to increase urine flow rate and minimize the radiation dose to the bladder wall.
Trial: NCT06252493
Drug: Contrast Media, Magnetic Resonance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarem 20ml will be injected during acquisition of contrast enhanced T1weighted fat saturated sequences, in keeping with standard of care MR enterography.
Trial: NCT06252493
Drug: Oral contrast media application
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be invited to drink as much as possible of an oral contrast solution consisting of a mixture of 1500-2000 ml of dilute barium or sorbitol (VoLumen or Breeza) and water. Breeza, and in the past VoLumen, is routine clinical practice at MGH. The solution comes already prepared in bottles, so there is no need to dilute or prepare. The investigators will just hand the bottle to the patient and will ask the patient to start drinking \~1 hour before the scan. By routine practice at MGH, the investigators give 3-4 bottles of Breeza, about 1500-2000ml.
Trial: NCT06160895
Drug: TQ-A3334 placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Trial: NCT05879523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous, single dose, multiple doses
Trial: NCT05628038
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Trial: NCT05628038
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)
Trial: NCT04799054
Drug: TransCon TLR7/8 Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon TLR7/8 Agonist will be administered as an IT injection
Trial: NCT06574594
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination
Trial: NCT06574594
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methotrexate continuation group : keep methotrexate
Trial: NCT05929768
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV